Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation-Reference-Cited by-同舟云学术

Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation

Published:2013-10-04 Issue:12 Volume:41 Page:2215-2224
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Bershas David A.,Ouellet Daniele,Mamaril-Fishman Donna B.,Nebot Noelia,Carson Stanley W.,Blackman Samuel C.,Morrison Royce A.,Adams Jerry L.,Jurusik Kristen E.,Knecht Dana M.,Gorycki Peter D.,Richards-Peterson Lauren E.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference16 articles.

1. Adams JL, Dickerson SH, Johnson NW, Kuntz K, Petrov K, Ralph JM, Rheault TR, Schaaf G, Stellwagen J, Tian X et al. (2009) inventors, no given assignee. Benzene sulfonamide thiazole and oxazole compounds. U.S. patent US2009/0298815 A1.

2. Étude comparative de la décarboxylation des acides (benzothiazolyl-2)-acétique, -3-propionique, -glyoxylique et -pyruvique

3. Subcellular pH and predicted pH-dependent features of proteins

4. Code of Federal Regulations (Revised as of April 1, 2013). Radioactive drugs for certain research uses. 21CFR361.1.

5. Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BRAF/Multikinase Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

2. Development and validation of an LC–MS/MS method to measure the BRAF inhibitors dabrafenib and encorafenib quantitatively and four major metabolites semi-quantitatively in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2023-09

3. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

4. Mechanistically Coupled PK (MCPK) Model to Describe Enzyme Induction and Occupancy Dependent DDI of Dabrafenib Metabolism;Pharmaceutics;2022-01-28

5. Pharmacokinetics, Mass Balance, and Metabolism of the Novel URAT1 Inhibitor [14C]HR011303 in Humans: Metabolism is Mediated Predominantly by UDP-glucuronosyltransferase;Drug Metabolism and Disposition;2021-12-03